Clinical trial NCT06795152: Rare Glycogen Storage Diseases Natural History Study
Official title: Rare Glycogen Storage Diseases Natural History Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Glycogen Storage Disease
GSD Type 0A
GSD Type 0B
GSD VII
Tarui Disease
GSD X
GSD XII
GSD XIII
GSD XV
Polyglucosan Body Myopathy 2
PGBM2
PRKAG2
Danon Disease
Keywords: glycogen storage disease
GSD
Tarui disease
Polyglucosan Body Myopathy 2
PGBM2
PRKAG2
Danon disease
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2025-01-27
Enrollment: 200
Sex: ALL
Minimum age (years): 0
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients with rare GSD, including 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome and Danon disease regardless of gender or ethnicity, are eligible for enrollment

Brief summary: The purpose of this study is to collect and study key medical data about several ultra-rare GSDs (Glycogen Storage Diseases) including, but not limited to, GSD types 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome and Danon disease.

Detailed description: The immediate goal of this research is to create a natural history database to collect information from individuals who have a rare GSD. A repository of clinical, laboratory, and biochemical information on individuals with a rare GSD will allow a more definitive description of the different subtypes to be developed, which will permit development of treatment strategies in the future.

Duke will be the only site where this study takes place. However, since these are rare disorders, participants who receive care at other institutions will be included. The investigators will collect retrospective data from patient charts on diagnosed individuals, as far back as necessary to capture the clinical course of their disorder. Prospective data collected from patient charts after enrollment will be captured as well. Participant's medical records will be continually reviewed for the duration of the study.

Data will be collected from medical records and will only pertain to clinically relevant information, including, but not limited to: demographic and diagnostic information, tissue biopsy results, medical and family history, review of systems, imaging studies, results of liver, muscle, and nerve function testing, and urine and blood laboratory results.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of a rare GSD, including 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome or Danon disease

  * Two variants in the gene associated with the specific GSD type (for autosomal recessive diseases)
  * One variant in the gene associated with the specific GSD type (for autosomal dominant or X-linked diseases)
  * Deficient enzyme activity in liver, muscle, skin fibroblast or other tissue
  * One variant in causative gene with evidence of disease, per a clinician
  * Histology as confirmed by a clinician
* Able to provide informed consent for self (adults) or affected individual (minor or adults with a legally authorized representative)
* Able to provide consent for release of medical records
* Pregnant women with a diagnosis of a rare GSD will be included

Exclusion Criteria:

* Unable to provide informed consent for participation for one's self or by legally authorized representative/legal guardian/parent

Primary outcomes:
measure: Progression of disease confirmed by medical record review
timeFrame: through study completion, an average of 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University
state: North Carolina
Study officials:
affiliation: Duke
name: Priya Kishnani, M.D.
role: PRINCIPAL_INVESTIGATOR
References: